Literature DB >> 8338351

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection.

R A Heijtink1, G A De Wilde, J Kruining, L Berk, J Balzarini, E De Clercq, A Holy, S W Schalm.   

Abstract

9-(2-Phosphonylmethoxyethyl)adenine (PMEA) was evaluated for its inhibitory effect on hepadnavirus replication in three different cell systems, i.e., human hepatoma cell lines HepG2 2.2.15 and HB611 (transfected with human hepatitis B virus (HBV)) and primary cultures of duck hepatocytes infected with duck hepatitis B virus (DHBV). PMEA inhibited HBV release from HepG2 2.2.15 cells and HB611 cells at a 50% inhibitory concentration (IC50) of 0.7 and 1.2 microM, respectively. Intracellular viral DNA synthesis was inhibited at concentrations equivalent to those required to inhibit virus release from the cells. DHBV secretion from duck hepatocytes was inhibited by PMEA at an IC50 of 0.2 microM. HBsAg secretion was inhibited by PMEA in a concentration-dependent manner in HB611 cells and DHBV-infected duck hepatocytes but not HepG2 2.2.15 cells. The 50% cytotoxic concentration, as measured by inhibition of [3H-methyl]deoxythymidine incorporation was 150 microM for the two human hepatoma cell lines and 40 microM for the duck hepatocyte cultures. In a pilot experiment PMEA was found to reduce the amounts of DHBV DNA in the serum of Pekin ducks.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338351     DOI: 10.1016/0166-3542(93)90050-s

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  27 in total

1.  In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Authors:  D Colledge; G Civitico; S Locarnini; T Shaw
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Authors:  Chin-chung Lin; Che Fang; Salete Benetton; Gui-fen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.

Authors:  C G Bridges; D L Taylor; P S Ahmed; T M Brennan; J M Hornsperger; J F Navé; P Casara; A S Tyms
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Christine Xu; Nanqun Zhu; David Lourenco; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.

Authors:  Julien Delmas; Olivier Schorr; Catherine Jamard; Craig Gibbs; Christian Trépo; Olivier Hantz; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.

Authors:  L Naesens; J Balzarini; N Bischofberger; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Authors:  Yuequan Shen; Natalia L Zhukovskaya; Michael I Zimmer; Sandriyana Soelaiman; Pamela Bergson; Chyung-Ru Wang; Craig S Gibbs; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

10.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.